BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37225693)

  • 21. Mutation analysis of tumor suppressor gene PTEN in patients with gastric carcinomas and its impact on PI3K/AKT pathway.
    Wen YG; Wang Q; Zhou CZ; Qiu GQ; Peng ZH; Tang HM
    Oncol Rep; 2010 Jul; 24(1):89-95. PubMed ID: 20514448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methylation and mutation of the inhibin‑α gene in human melanoma cells and regulation of PTEN expression and AKT/PI3K signaling by a demethylating agent.
    Ko H; Ahn HJ; Kim YI
    Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34958114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy.
    Yothaisong S; Dokduang H; Techasen A; Namwat N; Yongvanit P; Bhudhisawasdi V; Puapairoj A; Riggins GJ; Loilome W
    Tumour Biol; 2013 Dec; 34(6):3637-48. PubMed ID: 23832540
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PLEKHS1 drives PI3Ks and remodels pathway homeostasis in PTEN-null prostate.
    Chessa TAM; Jung P; Anwar A; Suire S; Anderson KE; Barneda D; Kielkowska A; Sadiq BA; Lai IW; Felisbino S; Turnham DJ; Pearson HB; Phillips WA; Sasaki J; Sasaki T; Oxley D; Spensberger D; Segonds-Pichon A; Wilson M; Walker S; Okkenhaug H; Cosulich S; Hawkins PT; Stephens LR
    Mol Cell; 2023 Aug; 83(16):2991-3009.e13. PubMed ID: 37567175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. RUNX2 overexpression and PTEN haploinsufficiency cooperate to promote CXCR7 expression and cellular trafficking, AKT hyperactivation and prostate tumorigenesis.
    Bai Y; Yang Y; Yan Y; Zhong J; Blee AM; Pan Y; Ma T; Karnes RJ; Jimenez R; Xu W; Huang H
    Theranostics; 2019; 9(12):3459-3475. PubMed ID: 31281490
    [No Abstract]   [Full Text] [Related]  

  • 26. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
    Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
    Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit.
    Bertacchini J; Mediani L; Beretti F; Guida M; Ghalali A; Brugnoli F; Bertagnolo V; Petricoin E; Poti F; Arioli J; Anselmi L; Bari A; McCubrey J; Martelli AM; Cocco L; Capitani S; Marmiroli S
    J Cell Physiol; 2019 Jul; 234(7):11188-11199. PubMed ID: 30565691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis.
    Jefferies MT; Cox AC; Shorning BY; Meniel V; Griffiths D; Kynaston HG; Smalley MJ; Clarke AR
    J Pathol; 2017 Dec; 243(4):442-456. PubMed ID: 29134654
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss of PTEN stabilizes the lipid modifying enzyme cytosolic phospholipase A₂α via AKT in prostate cancer cells.
    Vignarajan S; Xie C; Yao M; Sun Y; Simanainen U; Sved P; Liu T; Dong Q
    Oncotarget; 2014 Aug; 5(15):6289-99. PubMed ID: 25026288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Control of Glucocorticoid Receptor Levels by PTEN Establishes a Failsafe Mechanism for Tumor Suppression.
    Yip HYK; Chee A; Ang CS; Shin SY; Ooms LM; Mohammadi Z; Phillips WA; Daly RJ; Cole TJ; Bronson RT; Nguyen LK; Tiganis T; Hobbs RM; McLean CA; Mitchell CA; Papa A
    Mol Cell; 2020 Oct; 80(2):279-295.e8. PubMed ID: 33065020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
    Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
    Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: Enhanced surface expression and differential O-glycosylation of MT1-MMP.
    Kim S; Huang W; Mottillo EP; Sohail A; Ham YA; Conley-Lacomb MK; Kim CJ; Tzivion G; Kim HR; Wang S; Chen YQ; Fridman R
    Biochim Biophys Acta; 2010 Nov; 1803(11):1287-97. PubMed ID: 20620173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.
    Fu Y; Wey S; Wang M; Ye R; Liao CP; Roy-Burman P; Lee AS
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19444-9. PubMed ID: 19033462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid estrogen signaling negatively regulates PTEN activity through phosphorylation in endometrial cancer cells.
    Scully MM; Palacios-Helgeson LK; Wah LS; Jackson TA
    Horm Cancer; 2014 Aug; 5(4):218-31. PubMed ID: 24844349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression.
    Lau MT; Klausen C; Leung PC
    Oncogene; 2011 Jun; 30(24):2753-66. PubMed ID: 21297666
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2.
    Mao N; Gao D; Hu W; Gadal S; Hieronymus H; Wang S; Lee YS; Sullivan P; Zhang Z; Choi D; Rosen N; Sawyers CL; Gopalan A; Chen Y; Carver BS
    Cancer Res; 2020 Apr; 80(7):1428-1437. PubMed ID: 32015092
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling.
    Korkaya H; Paulson A; Charafe-Jauffret E; Ginestier C; Brown M; Dutcher J; Clouthier SG; Wicha MS
    PLoS Biol; 2009 Jun; 7(6):e1000121. PubMed ID: 19492080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.